Oramed Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Oramed Pharmaceuticals Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Aug 2021Aug 2020Aug 2019Aug 2018
Revenue & Gross Profit
Revenue0.001.342.702.702.712.702.45
Cost of Revenue0.190.000.000.000.00-0.09-0.09
Gross Profit-0.191.342.702.702.712.612.54
Operating Expenses
Research & Development6.328.9727.6420.9910.2413.5211.98
Selling, General & Administrative6.468.1415.665.944.233.724.08
Operating Expenses12.7817.1143.3026.9314.4717.2416.06
Operating Income-12.78-15.77-40.60-24.22-11.76-14.63-13.53
Other Income/Expense
Interest Income5.008.173.570.350.000.000.90
Interest Expense0.852.040.000.000.000.000.00
Other Income/Expense-7.2416.27-0.630.890.44-0.58-0.03
Income
Income Before Tax-15.925.09-37.66-22.99-12.20-14.06-12.73
Income Tax Expense3.180.100.100.000.000.300.00
Net Income-19.065.53-36.56-22.24-11.51-14.36-12.73
Net Income - Continuous Operations-19.105.09-37.76-22.990.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA-14.877.32-37.61-24.15-11.75-14.08-13.52
EBIT-15.077.13-37.66-24.22-11.76-14.09-13.53
Depreciation & Amortization0.190.200.060.080.000.000.00
Earnings Per Share
Basic EPS---1.00-1.001.00--1.00
Diluted EPS---1.00-1.001.001.00-1.00
Basic Shares Outstanding40.8340.3239.0028.4720.5317.4514.88
Diluted Shares Outstanding40.8340.5739.0028.4720.5317.5114.88